TABLE 1.
Relationship between HDL-C, macrophage RCT, and atherosclerosis in response to genetic manipulation and pharmacologic intervention in mice
| Tissue | Effect on HDL-C | Effect on macrophage RCT | Effect on atherosclerosis | |
|---|---|---|---|---|
| Genetic manipulation | ||||
| ApoA-I overexpression | Liver | Increase | Increase | Decrease |
| ApoA-I knockout | Whole body | Decrease | Decrease | Increase |
| SR-BI overexpression | Liver | Decrease | Increase | Decrease |
| SR-BI knockout | Whole body | Increase | Decrease | Increase |
| CETP expression | Liver | Decrease | ||
| LDLR +/+ mice | Increase | Decrease | ||
| LDLR −/− mice | Neutral to decrease | Increase | ||
| LCAT overexpression | Liver | Increase | Decrease | Increase |
| LCAT + CETP expression | Liver | Variable | Neutral | Neutral |
| LCAT knockout | Whole body | Decrease | Neutral | Variable |
| ABCA1 knockout | Macrophage | No change | Decrease | Increase |
| ABCG1 knockout | Macrophage | No change | Decrease | Decrease |
| ABCA1 + ABCG1 knockout | Macrophage | No change | Decrease | Increase |
| SR-BI knockout | Macrophage | No change | Neutral | Variable |
| Pharmacologic intervention | ||||
| LXR agonist | Variable | Increase | Decrease | |
| PPARα agonist | Variable | Increase | Decrease | |
| Ezetimibe | No change | Increase | Decrease | |